Common hepatitis C drugs available in Canada for adults
Treatments for all genotypes | |||||
| Brand name (generic name) | Genotypes | Image | Dosage schedule | Food requirements | Weeks of treatment |
Epclusa with or without ribavirin* | All |  | One tablet once daily | No food restrictions | 12 |
| Maviret (glecaprevir + pibrentasvir) | All |  | Three tablets once daily | Take with food | 8, 12 or 16 |
Treatment for specific genotypes | |||||
| Brand name (generic name) | Genotypes | Image | Dosage schedule | Food requirements | Weeks of treatment |
| Harvoni (ledipasvir + sofosbuvir) | 1a, 1b, 4, 5, 6 |  | One tablet once daily | No food restrictions | 8 or 12 |
Retreatment if Epclusa, Maviret or Harvoni failed to cure infection | |||||
| Brand name (generic name) | Genotypes | Image | Dosage schedule | Food requirements | Weeks of treatment |
| Vosevi (sofosbuvir + velpatasvir + voxilaprevir) | All |  | One tablet once daily | Take with food | 12 |
*ribavirin as a possible treatment addition | |||||
| Ibavyr (ribavirin) | 
| 1,000 mg for under 75 kg and 1,200 mg for 75 kg or more, twice daily | Take with food | See above | |
NOTE
This chart is not a complete list of Health Canada-approved treatments for hepatitis C. This chart lists common daily dosing schedules. People should always follow the dosing schedule prescribed by their healthcare provider. Healthcare providers can check for drug interactions between hepatitis C treatment and other drugs a person is taking with a pharmacist or at www.hep-druginteractions.org.
Disclaimer
CATIE endeavours to provide up-to-date and accurate information at the time of publication, but it should not be considered medical advice. Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner. CATIE resources may contain descriptions or depictions of sex, sexuality or drug use, with the goal of promoting public health. Any opinions expressed herein may not reflect the policies or opinions of CATIE or any partners or funders.
Acknowledgements
Epclusa®, Harvoni® and Vosevi™ are trademarks of Gilead Sciences, Inc., or its related companies. Images of Epclusa, Harvoni and Vosevi, copyright Gilead Sciences, Inc., or its related companies. Used with permission. Maviret™ is a trademark of AbbVie Corporation. Image of Maviret is copyright AbbVie Corporation. Used with permission. Ibavyr™ is a trademark of Pharmascience Inc. Images used with permission.
Production of this publication has been made possible through a financial contribution from the Public Health Agency of Canada and the Ontario Ministry of Health. The views expressed herein do not necessarily represent the views of the Public Health Agency of Canada or other funders.